(Q44529535)

3 December 2017

Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone--a factorial study (English)

1 reference

3 December 2017

2

1 reference

3 December 2017

R R Henry

1

1 reference

3 December 2017

V A Fonseca

3

1 reference

3 December 2017

M Z Chou

4

1 reference

3 December 2017

R Teng

5

1 reference

3 December 2017

G T Golm

6

1 reference

3 December 2017

R B Langdon

7

1 reference

3 December 2017

K D Kaufman

8

1 reference

3 December 2017

H Steinberg

9

1 reference

3 December 2017

B J Goldstein

10

1 reference

3 December 2017

29 August 2013

1 reference

Diabetes, Obesity and Metabolism

3 December 2017

1 reference

3 December 2017

16

1 reference

3 December 2017

3

1 reference

3 December 2017

223-230

1 reference

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

3 December 2017

1 reference

Factors associated with intensification of oral diabetes medications in primary care provider-patient dyads: a cohort study

21 January 2018

1 reference

Clinical inertia in general practice: widespread and related to the outcome of diabetes care

21 January 2018

1 reference

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

21 January 2018

1 reference

Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes

21 January 2018

1 reference

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.

21 January 2018

1 reference

Pioglitazone: side effect and safety profile

21 January 2018

1 reference

Thiazolidinediones and PPARγ agonists: time for a reassessment

21 January 2018

1 reference

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men.

21 January 2018

1 reference

Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12194

1 reference

3 December 2017

1 reference